Yeah fair point on the medical MLLM stuff. FDA and modular approaches have never been best friends. That's actually why I'm most curious to see how it plays out - the ArXiv activity around safety grafting has been picking up but whether regulators actually buy it vs demanding full retraining... we'll see. The OpenAI platformization one I'll admit feels safer. Curious though - do you think the window's already closing or is there still runway for the picks and shovels players?